Exasol Announces Expanded Capabilities of Its Analytics SaaS Database, Including ETL Integration
3.5.2022 11:00:00 EEST | Business Wire | Press release
Exasol, the market leading high-performance analytics database, has announced that from today, Exasol SaaS – the scalable, consumption-based SaaS database based on Amazon Web Services (AWS) – now natively interfaces with Keboola, a cloud-based Data Stack as a Service platform. Keboola provides the first complete solution for data engineers, data analysts, and analytics engineers to deliver on the full spectrum of data demands – from data ingestion to automation. Users will benefit from a built-in function that connects them directly to Keboola from Exasol’s SaaS interface. The Keboola low-code platform provides more than 250 integrations for building ETL/ELT and other pipelines, automation, one-click workflows with integrated business case templates, as well as enterprise grade data governance over the entire stack. It’s a combination that provides improved data accuracy and reduces the time to value.
Commenting on the news, Milan Veverka, VP of Alliances at Keboola said: “We believe that by surrounding ourselves with amazing people, we can achieve anything. That's why we focus on building partnerships that matter. Partnerships with companies that have a similar mindset as we do - empowering everyone to make data-driven decisions. Keboola and Exasol provide great solutions together. We built a simple to use, cost-effective and easy to maintain Data Stack as a Service while Exasol provides its fast in-memory database that helps customers to get to their solution. Together we will make both the implementation and the queries themselves much faster for shared customers.”
In addition to the new collaboration with Keboola, Exasol has introduced a series of new product capabilities that expand on its fully managed, SaaS offering. The new product capabilities will further enhance a customer’s ability to access data-led insights quickly, without needing to manage hardware infrastructures. These innovations include:
- Enhanced AI/ML capabilities: Customers can now solve complex analytics challenges with ease, such as predictive analytics, by bringing in AI/ML algorithms directly to the data. Operationalizing ML models will also bring maximum performance within the database to its users.
- Data virtualization support: Analysts will be able to access objects from external sources without the need for migrating data. This support will also eliminate the need for the costly management of duplicate data. It will allow users to more easily access their data – whether it’s stored locally or in the cloud – and set-up or create a logical data warehouse.
- Amazon SageMaker extension: Exasol SaaS now supports a SageMaker Extension, enabling users to develop end-to-end machine learning projects on data stored in Exasol using the Amazon SageMaker Autopilot service. Doing so mean users can turn data into actionable insights in a matter of minutes.
“When it comes to an organization’s data strategy, data leaders are looking for the confidence to modernize with market-proven, enterprise capabilities that offer flexible migration paths – often to the cloud – at a pace and time that fits with budget and resource constraints,” says Donald Kaye, Chief Commercial Officer at Exasol. The impact of this decision can be profound: affecting costs, the pace of innovation, production releases, marketing penetration and security, to name just a few. “To address the complex challenges organizations face when looking to garner actionable insight from their data, we announced, in February, the strengthening of our hybrid cloud proposition by making our high-performance analytics database available via Exasol SaaS.”
Exasol SaaS is available in two versions. The Exasol SaaS Standard Edition delivers industry leading performance on-demand for organizations with smaller data volumes who don’t require advanced analytics and data integration features or extended support. The Exasol SaaS Enterprise Edition is designed for organizations that require multi-departmental analytics environments, need to perform ML or AI in the database, or have complex requirements in terms of data integration and data virtualization.
Both versions of Exasol SaaS are available here.
About Exasol
Exasol was founded in 2000 with the vision to transform how organizations use data. Today, Exasol’s analytics database – the fastest in the world – is trusted by the world’s most ambitious organizations. With offices in several locations across the US and Europe, Exasol is committed to delivering flexible, scalable and powerful analytics solutions to customers wherever they are, in the cloud – public or private - or on-premises.
Exasol – the leading Performance Analytics Database powering insights from the world’s data.
Learn more at: www.exasol.com and follow us on social media: LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005032/en/
Contact information
Isabella Alder, EMEA PR Manager at Exasol
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
